Merck KGaA, Darmstadt, Germany, and SpringWorks Therapeutics, Inc. announced on April 28, 2025, that they have entered into a definitive agreement for Merck KGaA to acquire SpringWorks. The purchase price is $47 per share in cash.
This transaction represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion based on SpringWorks’ cash balance as of December 31, 2024. The offer provides a premium of 26% to SpringWorks’ unaffected 20-day volume-weighted average price on February 7, 2025.
The acquisition has been unanimously approved by both companies' Boards of Directors and is expected to close in the second half of 2025, subject to customary closing conditions, including shareholder and regulatory approvals. This deal is set to accelerate Merck KGaA's sustainable growth in its Healthcare business and expand SpringWorks' therapeutic innovations globally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.